miR-22 inhibition reduces hepatic steatosis via FGF21 and FGFR1 induction
Ying Hu, Huixin Liu, Prasant Kuma Jena, Lili Sheng, Mohamed R. Ali, Yu‐Jui Yvonne Wan
Abstract
BACKGROUND & AIMS: could be a metabolic silencer. METHODS: inhibitor alone and in combination with obeticholic acid (OCA) for the treatment of steatosis. RESULTS: inhibitor and OCA were effective in treating diet-induced steatosis, both alone and in combination. The combined treatment was the most effective at improving insulin sensitivity, releasing glucagon-like peptide 1, and reducing hepatic triglyceride in obese mice. CONCLUSION: enhances hepatic FGF21 and activates AMPK, which could be a novel approach to treat steatosis and insulin resistance. LAY SUMMARY: inhibition is a promising therapeutic option which could be used in combination with obeticholic acid.